Children's Health Defense By
Maryland-based Emergent BioSolutions this month signed a new contract with the U.S. Department of Defense (DOD) to supply the U.S. military with its BioThrax anthrax vaccine over at least the next five years, Fierce Pharma reported.
The indefinite-delivery, indefinite-quantity contract, announced Jan. 11 by the company, has a maximum value of $235.8 million. According to Yahoo Finance, “The vaccine is intended for use by all branches of the United States military as pre-exposure prophylaxis (PrEP) for anthrax disease.”
Under the contract, Emergent is guaranteed a $20.1 million purchase, with future orders of an estimated $20 million or more for each of the remaining years of the initial five-year term.
After the initial term, the contract has an option for an additional five-year extension, potentially extending the deal to 2033, according to Fierce Pharma.
BioThrax is the only vaccine approved by the U.S. Food and Drug Administration (FDA) for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease, Yahoo Finance reported. Another anthrax vaccine in the company’s portfolio, Cyfendus, is used only for post-exposure prophylaxis in adults 18 and over.
According to Yahoo Finance, anthrax is an infectious disease caused by Bacillus anthracis. It occurs naturally in soil, and commonly affects domestic and wild animals.
People can contract anthrax if they come in contact with infected animals or contaminated animal products, through skin contact, ingestion and inhalation, The Defense Post reported. It can cause organ damage, inflammation of the brain and spinal cord, and death…
READ FULL ARTICLE HERE… (childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Be First to Comment